Association between urinary angiotensinogen levels and renal and cardiovascular prognoses in patients with type 2 diabetes mellitus

Journal of Diabetes Investigation

Volumn 3, Issue 3, 2012, Pages 318-324

  Sawaguchi, Makoto ^a   Araki, Shin Ichi ^a   Kobori, Hiroyuki ^d   Urushihara, Maki ^d   Haneda, Masakazu ^b   Koya, Daisuke ^c   Kashiwagi, Atsunori ^a   Uzu, Takashi ^a   Maegawa, Hiroshi ^a  

^a SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

^b ASAHIKAWA MEDICAL COLLEGE   (Japan)

^c KANAZAWA MEDICAL UNIVERSITY   (Japan)

^d TULANE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

Angiotensinogen; Diabetes mellitus; Glomerular filtration rate

Indexed keywords

ANGIOTENSINOGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; ALBUMINURIA; ANGINA PECTORIS; ARTICLE; BRAIN HEMORRHAGE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; DISEASE DURATION; FEMALE; GLOMERULUS FILTRATION RATE; HEART INFARCTION; HEMODIALYSIS; HUMAN; KIDNEY BLOOD FLOW; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SEX DIFFERENCE; STROKE; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 84861965119     PISSN: 20401116     EISSN: 20401124     Source Type: Journal    
DOI: 10.1111/j.2040-1124.2011.00172.x     Document Type: Article

References (26)

1. Adler AI, Stevens RJ, Manley SE, et al. Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int 2003; 63: 225-232.
2. Araki S, Haneda M, Koya D, et al. Reduction in microalbuminuria as an integrated indicator for renal and cardiovascular risk reduction in patients with type 2 diabetes. Diabetes 2007; 56: 1727-1730.
3. Ninomiya T, Perkovic V, de Galan BE, et al. Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes. J Am Soc Nephrol 2009; 20: 1813-1821.
4. Lewis EJ, Hunsicker LG, Bain RP, et al. The Collaborative Study Group. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 1993; 329: 1456-1462.
5. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861-869.
6. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851-860.
7. Koya D, Araki S, Haneda M. Therapeutic management of diabetic kidney disease. J Diabetes Invest 2011; 2: 248-254.
8. Ingelfinger JR, Zuo WM, Fon EA, et al. In situ hybridization evidence for angiotensinogen messenger RNA in the rat proximal tubule. An hypothesis for the intrarenal renin angiotensin system. J Clin Invest 1990; 85: 417-423.
9. Kobori H, Nangaku M, Navar LG, et al. The intrarenal renin-angiotensin system: from physiology to the pathobiology of hypertension and kidney disease. Pharmacol Rev 2007; 59: 251-287.
10. Katsurada A, Hagiwara Y, Miyashita K, et al. Novel sandwich ELISA for human angiotensinogen. Am J Physiol Renal Physiol 2007; 293: F956-F960.
11. Kobori H, Ohashi N, Katsurada A, et al. Urinary angiotensinogen as a potential biomarker of severity of chronic kidney diseases. J Am Soc Hypertens 2008; 2: 349-354.
12. Kobori H, Alper AB Jr, Shenava R, et al. Urinary angiotensinogen as a novel biomarker of the intrarenal renin-angiotensin system status in hypertensive patients. Hypertension 2009; 53: 344-350.
13. The Committee of the Japan Diabetes Society on the Diagnostic Criteria of Diabetes Mellitus. Report of the Committee on the classification and diagnostic criteria of diabetes mellitus. J Diabetes Invest 2010; 1: 212-228.
14. Matsuo S, Imai E, Horio M, et al. Collaborators developing the Japanese equation for estimated GFR. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 2009; 53: 982-992.
15. Yasue S, Masuzaki H, Okada S, et al. Adipose tissue-specific regulation of angiotensinogen in obese humans and mice: impact of nutritional status and adipocyte hypertrophy. Am J Hypertens 2010; 23: 425-431.
16. Kobori H, Nishiyama A, Harrison-Bernard LM, et al. Urinary angiotensinogen as an indicator of intrarenal angiotensin status in hypertension. Hypertension 2003; 41: 42-49.
17. Ohashi N, Urushihara M, Satou R, et al. Glomerular angiotensinogen is induced in mesangial cells in diabetic rats via reactive oxygen species - ERK/JNK pathways. Hypertens Res 2010; 33: 1174-1181.
18. Hsieh TJ, Zhang SL, Filep JG, et al. High glucose stimulates angiotensinogen gene expression via reactive oxygen species generation in rat kidney proximal tubular cells. Endocrinology 2002; 143: 2975-2985.
19. Saito T, Urushihara M, Kotani Y, et al. Increased urinary angiotensinogen is precedent to increased urinary albumin in patients with type 1 diabetes. Am J Med Sci 2009; 338: 478-480.
20. Yamamoto T, Nakagawa T, Suzuki H, et al. Urinary angiotensinogen as a marker of intrarenal angiotensin II activity associated with aeterioration of renal function in patients with chronic kidney disease. J Am Soc Nephrol 2007; 18: 1558-1565.
21. Urushihara M, Kondo S, Kagami S, et al. Urinary angiotensinogen accurately reflects intrarenal Renin-Angiotensin system activity. Am J Nephrol 2010; 31: 318-325.
22. Sachetelli S, Liu Q, Zhang SL, et al. RAS blockade decreases blood pressure and proteinuria in transgenic mice overexpressing rat angiotensinogen gene in the kidney. Kidney Int 2006; 69: 1016-1023.
23. Liu F, Brezniceanu ML, Wei CC, et al. Overexpression of angiotensinogen increases tubular apoptosis in diabetes. J Am Soc Nephrol 2008; 19: 269-280.
24. Najafian B, Mauer M. Progression of diabetic nephropathy in type 1 diabetic patients. Diabetes Res Clin Pract 2009; 83: 1-8.
25. Araki S, Haneda M, Koya D, et al. Association between urinary type IV collagen level and deterioration of renal function in type 2 diabetic patients without overt proteinuria. Diabetes Care 2010; 33: 1805-1810.
26. Ogawa S, Kobori H, Ohashi N, et al. Angiotensin II type 1 receptor blockers reduce urinary angiotensinogen excretion and the levels of urinary markers of oxidative stress and inflammation in patients with type 2 diabetic nephropathy. Biomark Insights 2009; 4: 97-102.